Remove Blood Pressure Remove Diabetes Remove Kidney Disease
article thumbnail

One Injection of Novel Drug Cuts Systolic Blood Pressure by Up to 12 mmHg

DAIC

Akshay Desai, MD “Compared to placebo, a single injection of zilebesiran resulted in clinically meaningful reductions in blood pressure at three months when added to commonly used antihypertensive treatments,” said Akshay Desai, MD, MPH , a cardiologist at Brigham and Women’s Hospital in Boston and a study coauthor. “In

article thumbnail

Abstract 4137914: Eligibility for Semaglutide in US Adults with Diabetes and Potentially Preventable Cardiovascular Events Projected from the SUSTAIN-6 Trial

Circulation

Background:The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial showed cardiovascular disease (CVD) benefits of semaglutide therapy in patients with type 2 diabetes mellitus (T2DM).Purpose:To year follow-up time).Results:Among

article thumbnail

Microvascular disease, modifiable risk factor profiles and incident arrhythmias in type 2 diabetes

Heart BMJ

Background To assess the roles of diabetic microvascular disease and modifiable risk factors and their combination in the development of arrhythmias. Methods We included participants with type 2 diabetes (T2D) who were free of arrhythmias during recruitment in the UK Biobank study.

article thumbnail

Kidney Week 2023: Top Ten Takeaways

Cardiometabolic Health Congress

Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidney disease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.

article thumbnail

Abstract 4147960: Intensive treatment compared to Standard for hypertension in elderly patients, is it safe and effective? A Systematic Review and Meta-Analysis

Circulation

Introduction:Blood pressure targets for the elderly are still controversial, there is a lack of certainty about the benefit and safety of targeting ≤ 130mmHg systolic blood pressure. of patients had cardiovascular disease, 10.9% diabetes, and 15.5% chronic kidney disease.

article thumbnail

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

DAIC

AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure. mmHg in office systolic blood pressure (oSBP) at six months when compared to control patients. Suman Pasupuleti, M.D.

Pacemaker 105
article thumbnail

Finerenone’s Early Heart Failure Impact

CardiacWire

Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), blocking the mineralocorticoid receptor and its blood pressure effects. Finerenone is already approved to reduce cardiovascular and kidney disease risks in patients with type 2 diabetes-associated CKD, but not for HF.